Doxazosin - Pfizer
Alternative Names: Alfadil; Cardenalin; Cardular; Cardura; Cardura XL; Carduran; Dedralen; Diblocin; Doxaben; Doxazosin mesylate; Normothen; Supressin; Tensiobas; UK 33274; UK 3327427; ZofluxLatest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Developer Almirall S.A.; AstraZeneca; Fisons; Libbs Farmaceutica; Lifepharma; Pfizer; Purepac Pharmaceutical; Teva Pharmaceutical Industries; Viatris Inc
- Class Antihypertensives; Quinazolines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Benign prostatic hyperplasia; Hypertension
Most Recent Events
- 25 Feb 2005 The US FDA has given final marketing approval for a sustained-release formulation of doxazosin in benign prostatic hyperplasia
- 23 Nov 2004 A Pharmacoeconomic study has been added to the Men's Health therapeutic trials section
- 02 Sep 2004 Health Canada has approved the combination treatment of finasteride and doxazosin in reducing the risk of symptomatic progress of benign prostatic hyperplasia